Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)

Abstract Background Emicizumab is a subcutaneously administered humanized, bispecific, monoclonal antibody approved for prophylaxis in people with hemophilia A. Methods HAVEN 5 (NCT03315455) is a randomized, open‐label, phase 3 study of individuals aged ≥12 years with severe hemophilia A without fac...

Full description

Bibliographic Details
Main Authors: Renchi Yang, Shujie Wang, Xuefeng Wang, Jing Sun, Ampaiwan Chuansumrit, Jianfeng Zhou, Christophe Schmitt, Wanling Hsu, Jeffrey Xu, Lindong Li, Tiffany Chang, Xielan Zhao
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
clinical trials
emicizumab
factor VIII
hemophilia A
prophylaxis
randomized
Online Access:https://doi.org/10.1002/rth2.12670

Internet

https://doi.org/10.1002/rth2.12670

Similar Items